Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Poly-ICLC (Hiltonol®) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot Study

NCT03721679 is registered in ClinicalTrials.gov with Oncovir, Inc. as lead sponsor.

NCT NCT03721679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03721679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Poly-ICLC (Hiltonol®) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot Study
Lead sponsor
Oncovir, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
September 25, 2018
Completion date
January 26, 2021
Enrollment
7 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid cancer